Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss ...

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

A new study found that children whose mothers took an essential vitamin early in pregnancy had significantly higher verbal ...

Novo Nordisk is cutting the cost of its blockbuster weight-loss drug Wegovy in half for U.S. patients paying cash through its ...

The home shipments — which will be fulfilled by CenterWell Pharmacy — include Wegovy injections of 0.25 mg, 0.5 mg, 1 mg, 1.7 ...

NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients ...

Novo Nordisk, the manufacturer of Weggovy, is growing its offerings by creating NovoCare Pharmacy, a direct-to-patient (DTP) ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market impact. Read more on ALT stock here.

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer. Hims & Hers Health Inc.’s stock plunged last week when the ...

While Ozempic is actually intended for people with ... Another option we found progresses each month from 0.2mg to 0.4mg, 0.8mg, 1.2mg, 1.8mg, and finally to 2.2mg at six months.